 WALTHAM, Mass., May 03, 2021 GLOBE NEWSWIRE -- Entasis Therapeutics Holdings Inc. Nasdaq: ETTX, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has completed the initial closing of an approximately 7.5 million stock and warrant issuance to a subsidiary of Innoviva Inc. Nasdaq: INVA Innoviva, pursuant to a securities purchase agreement signed on May 3, 2021. Upon satisfaction of certain closing conditions, including approval by Entasis stockholders, Innoviva will purchase the balance of the 20 million in Entasis common stock and warrant securities in a second closing that is anticipated later in the second quarter of 2021 excluding the consideration payable upon exercise of warrants, if any. 